Article Text

Download PDFPDF
CASE REPORT
SLE presenting as demyelinative autoimmune visual loss
  1. Ami Schattner1,
  2. Shilo Voichanski2,
  3. Livnat Uliel3
  1. 1Faculty of Medicine, Hebrew University, Jerusalem, Israel
  2. 2Department of Ophthalmology, Shaare Zedek Medical Center, Jerusalem, Israel
  3. 3Department of Imaging, Laniado Hospital, Netanya, Israel
  1. Correspondence to Professor Ami Schattner, amischatt{at}gmail.com

Summary

A healthy 38-year-old woman developed sudden unilateral vision loss due to retrobulbar optic neuritis in the wake of varicella-zoster virus infection. She had no further central nervous system (CNS) lesions. Antinuclear antibodies (ANA) and anti-aquaporin 4 antibodies were found, consistent with neuromyelitis optica (NMO). Later, serial MRIs showed dynamic short-segment and long-segment myelitis lesions, ANA titre increased and additional autoantibodies were found including anti-dsDNA, anti-chromatin/nucleosome and antiphospholipid antibodies. In that setting, NMO can be regarded a rare presenting manifestation of systemic lupus erythematosus (SLE). The relevant literature is reviewed and the implications of NMO spectrum disorder demyelinating syndromes as the first manifestation of SLE (with or without antiphospholipid syndrome) (APS) or their later development (in a patient diagnosed with SLE) as part of the spectrum of neuropsychiatric SLE are analysed in view of recent research developments in the field.

  • immunology
  • cranial nerves
  • neuroopthalmology
  • visual pathway
  • connective tissue disease

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors All authors were involved in the patient’s diagnostic and treatment decisions. LU analysed the imaging. AS prepared the manuscript and SV and LU participated in its preparation.

  • Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.